Compare Biogen Inc (BIIB) vs Carparts.Com Inc (PRTS) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

PRTS trades at $6.35, up 0.47% today, with a bullish technical signal from moving averages. The company reported Q2 2026 earnings that beat expectations, with a net loss of -$0.43 per share versus -$0.85 expected. However, fundamentals show declining revenue from $676M in 2023 to $548M in 2025 and negative net income margins. A reverse stock split was executed on May 26, 2026, to maintain Nasdaq compliance.

The outlook is mixed: analyst consensus is 60% buy with no sell ratings, but persistent losses and negative cash flow from operations pose significant risks. Investment opportunity hinges on operational turnaround and proprietary data leverage, while high volatility and competitive pressures require caution.